Blood Draw
OtherVenous blood sampling into Tempus tube for RNA-sequencing
NCT Number: NCT07131969
Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure.
Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.
Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.
Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
University Hospitals Birmingham, Birmingham, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Venous blood sampling into Tempus tube for RNA-sequencing
Time frame: From enrolment until at least 1-year
Time frame: From enrolment to at least one year
30-day and 1-year survival without transplant
Time frame: From enrolment
Number of days stayed in ICU and in-hospital
Time frame: From enrolment until death (at least until 1year)
Death without transplant
University of Cambridge
Other
Transcriptional Analysis of Mechanisms and Predictors in Acute Liver Failure and Sepsis
Acronym: MAP-ALF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05146336
Acute Liver Failure, Acute Respiratory Distress Syndrome
Klagenfurt, Austria
View Trial DetailsNCT03270774
Acute Liver Failure, Brain Diseases
View Trial DetailsNCT06515145
Acute Liver Failure, Brain Diseases
New Delhi, National Capital Territory of Delhi, India
View Trial DetailsNCT07556055
Acute Liver Failure, Digestive System Diseases
View Trial Details